News

Findings published in JDD suggest topical tranexamic acid can be used as first-line monotherapy.

The expected PDUFA date is December 16, 2023.

Brella received FDA clearance last week for improving excessive underarm sweating.

Researchers said responses may depend on prior immunotherapy.

The findings suggest a need to conduct cancer screening by a detailed history and comprehensive clinical examination in patients with PsA.

Researchers said occlusive materials used in gloves can lead to irritant contact dermatitis.

Click here to answer this week's poll.

The combination of punica granatum, citrus sinesis, f. cistanche, and centella asiatica revealed improved skin moisturization, radiance, and elasticity in a new study.

This week's edition of the Mainstream Patient features stories about the risks of phenol peels, the pros and cons of skin cycling, how to prevent stretch marks during pregnancy, and more.

The association was significant after adjusting for sociodemographic factors, hair status, dietary intake, lifestyle, and psychological status.

Data from the KEYNOTE-942 trial was presented at the American Association for Cancer Research Annual Meeting 2023.

The Minghui Pharmaceutical study met both primary and all key secondary endpoints.

ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.

A review of prior research shows that topical beeswax may have several dermatologic benefits.

Researchers said several geographic and demographic factors or changes have led to new skin manifestations.

April is National Rosacea Month. Recent data has indicated a correlation between rosacea and certain cardiovascular, neurologic, endocrine, and gastrointestinal disorders. Steve Daveluy, MD, FAAD shares insight on that, plus several new and exciting therapies available.

Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.

Patients can achieve reduced excessive underarm sweating after one in-office treatment.

Researchers compiled future research directions and therapeutic and clinical developments in psoriasis.

This will be the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint.

Merck and Eisai discontinued the trial based on recommendations of an independent data monitoring committee.

Researchers said the drug successfully altered C. acnes strains and more in a recent study.

HHS’ cybersecurity agency warns about KillNet, other threats emerging and expected to continue this year.

In this week’s Pointers with Portela, the 208SkinDoc discusses the safety of made-to-fade tattoos.

Researchers in a recent study said women are more likely to experience these effects, which can affect internal health.

Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.

It has been hypothesized that some lipid-lowering drugs are disease-modifying for psoriasis, and the use of lipid-lowering drugs in the management of psoriasis symptoms is currently being explored

Despite a lack of FDA-approved treatments and management options for patients with vitiligo, both dermatologists and patients alike have options for care.

The study was the first to examine the fruit's properties as a wound-healing agent and skin protectant.

The skin microbiome varies from person to person based on sex, age, body location, antimicrobial peptide presence, and immune function.